Kim, Soo-Kyoung
Chong, Catherine D.
Dumkrieger, Gina
Ross, Katherine
Berisha, Visar
Schwedt, Todd J.
Funding for this research was provided by:
the Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-15-1-0286, W81XWH-19-1-0534)
Article History
Received: 14 January 2020
Accepted: 2 April 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: Mayo Clinic Institutional Review Board, Phoenix VA Health Care System Institutional Review Board, and U.S. Department of Defense Human Research Protection Office approvals were obtained prior to initiation of study procedures. Each research participant underwent an informed consent process during which the potential risks and benefits of study participation were discussed.
: Not applicable.
: The authors declare that they have no competing interests.--- Todd J. Schwedt, MD, has served as a consultant for Alder, Allergan, Amgen, ATI, Aural Analytics, Avanir, Biohaven, Cipla, Click Therapeutics, Dr. Reddy’s Laboratories, Eli Lilly, Equinox, Ipsen Bioscience, Nocira, Novartis, Promius Pharma, Second Opinion, Teva, and Xoc. He holds stock options in Aural Analytics, Nocira, and Second Opinion and has received research funding from Amgen.